REFERENCES
- Mt-Isa S, Tzoulaki I, Callreus T, Micaleff A, Ashby D. Weighing benefit-risk of medicines: concepts and approaches. Drug Discov Today Technol 2011; 8(1):e29–e35.
- Ioannidis JP, Evans SJ, Gøtzsche PC, . Better reporting of harms in randomized 390 trials: an extension of the CONSORT statement. Ann Intern Med 2004; 141(10):781–788.
- Rothwell PM. External validity of randomised controlled trials: “to whom do the results of this trial apply?”. Lancet 2005; 365(9453):82–93.
- Vandenbroucke JP. Benefits and harms of drug treatments. Br Med J 2004; 329(7456):2–3.
- Moher D. CONSORT: an evolving tool to help improve the quality of reports of randomized controlled trials. Consolidated Standards of Reporting Trials. J Am Med Assoc 1998; 279:1489–1491.
- Pitrou I, Boutron I, Ahmad N, . Reporting of safety results in published reports of randomized controlled trials. Arch Intern Med 2009; 169(19):1756–1761.
- Williams B. Drug treatment of hypertension. Br Med J 2003; 326:61–62.
- Shukralla AA, Tudur-Smith C, Powell GA, . Reporting of adverse events in randomised controlled trials of antiepileptic drugs using the CONSORT criteria for reporting harms. Epilepsy Res 2011; 97:20–29.
- Bibawy H, Cossu A, Cogan S, . Reporting of harms and adverse events in otolaryngology journals. Otolaryngol Head Neck Surg 2009; 140(2): 241–244.
- Breau RH, Gaboury I, Scales CD Jr, . Reporting of harm in randomized controlled trials published in the urological literature. J Urol 2010; 183(5): 1693–1697.
- Chowers MY, Gottesman BS, Leibovici L, . Reporting of adverse events in randomized controlled trials of highly active antiretroviral therapy: systematic review. J Antimicrob Chemother 2009; 64(2):239–250.
- Ethgen M, Boutron I, Steg PG, et al. Reporting of harm in randomized controlled trials evaluating stents for percutaneous coronary intervention. Trials 2009; 10:29. Available from http://www.trialsjournal.com/content/10/1/29 ( Accessed 19 March 2011).
- Ethgen M, Boutron I, Baron G, . Reporting of harm in randomized, controlled trials of non pharmacological treatment for rheumatic disease. Ann Intern Med 2005; 143(1):20–25.
- Begg C, Cho M, Eastwood S, . Improving the quality of reporting of randomized controlled trials. The CONSORT statement. J Am Med Assoc 1996; 276(8):637–639.
- Han C, Kwak KP, Marks D, . The impact of the CONSORT statements on reporting of randomised clinical trials in psychiatry. Contemp Clin Trials 2009; 30:116–122.
- Plint ACMoher D, Morrison A, . Does the CONSORT checklist improve the quality of reports of randomised controlled trials? A systematic review. Med J Aust 2006; 185(5):263–267.
- Loke YK, Derry S. Reporting of adverse drug reactions in randomised controlled trials – a systematic survey. BMC Clin Pharmacol 2001; 1:3.
- Kirkham JJ, Dwan KM, Altman DG, . The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews. Br Med J 2010; 340:c365.
- EQUATOR Group. EQUATOR Network, 2012. Available from http://www.equator-network.org/ ( Accessed 18 April 2012).